Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NCT02921022 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02921022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02921022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 31, 2016
Completion date
October 31, 2026
Enrollment
110 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic ductal adenocarcinoma, pancreatic cancer